ARTICLE | Clinical News
Vidaza azacitidine regulatory update
January 5, 2009 8:00 AM UTC
The EC approved Vidaza azacitidine from Celgene to treat myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myelogenous leukemia (AML) in adults who are not eligible for...